Article
AstraZeneca raises stakes in obesity drug race with Eccogene deal
Rating:
0.0
Views:
39
Likes:
1
Library:
1
AstraZeneca placed a potential $2 billion bet on the booming anti-obesity drug market on Thursday, licensing an experimental pill from China's Eccogene that it believes could cause fewer side effects than current injectable treatments.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value